Spark’s Gene Therapy SPK-8011 to Treat Hemophilia A and B Advance in Clinical Trials – Hemophilia News Today
|
Spark's Gene Therapy SPK-8011 to Treat Hemophilia A and B Advance in Clinical Trials
Hemophilia News Today Three patients who received SPK-8011 — a gene therapy developed by Spark Therapeutics — for hemophilia A show increased production of clotting factor VIII without any safety issues reported, says the company. The patients are the first to receive the … |
